![conference banner](/images/conference-banner.jpeg)
摘要
背景:重度抑郁症(MDD)及其对抗抑郁药物的频繁部分反应是一个主要的健康问题,因此也是一个重要的研究重点。尽管努力,MDD的发病机制和抗抑郁作用机制仅部分了解。在过去的几年里,人们提出需要重新考虑抑郁症和精神疾病的分类,以便提供一种更密切地反映与疾病发病机制相关的生物学背景及其在治疗中的作用/意义的疾病学。美国国家心理健康研究所(NIMH)提出的分类,即研究领域标准(RDoC),可能是指导这一方向研究的一个关键框架。 方法:在PubMed和谷歌学者数据库上进行文献检索,以检索有关抗抑郁药对特定RDoC结构的影响的数据。此外,通过药物库数据库确定了感兴趣的药物的靶标,并讨论了它们在RDoC构建中的可能功能。 讨论:在这篇综述中,我们总结并讨论了临床前和临床研究结果的意义,这些研究是对与抑郁表型和抗抑郁作用相关的特定RDoC范式的研究。 结论:RDoC框架可能有助于进一步使用抗抑郁药物和开发针对特定抑郁症状的新化合物。
关键词: 研究领域标准,重度抑郁症,抗抑郁药,行为范式,RDoC构建,药物靶点。
Current Medicinal Chemistry
Title:Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression
Volume: 28 Issue: 22
关键词: 研究领域标准,重度抑郁症,抗抑郁药,行为范式,RDoC构建,药物靶点。
摘要:
Background: Major Depressive Disorder(MDD) and its frequent partial response to antidepressants are a major health concern and therefore an important focus of research. Despite the efforts, MDD pathogenesis and the mechanisms of antidepressant action are only partially understood. In the last few years, the need of rethinking the classification of depressive disorders and psychiatric disorders, in general, has been suggested, in order to provide a nosology that reflects more closely the biological background associated with disease pathogenesis and its role/significance in treatment. The classification proposed by the National Institute of Mental Health (NIMH), namely the research domain criteria (RDoC), may represent a key framework to guide research in this direction.
Methods: A literature search was performed on PubMed and Google Scholar databases in order to retrieve data regarding Antidepressants effects on specific RDoC constructs. Further, the targets of drugs of interest were identified through the Drug bank database, and their possible function within RDoC constructs was discussed.
Discussion: In this review, we summarize and discuss the significance of the results of pre-clinical and clinical studies investigating specific RDoC paradigms relevant to depressive phenotypes and antidepressant effects.
Conclusion: The RDoC framework may facilitate a more specific use of antidepressants based on the individual’s spectrum of symptoms and the development of new compounds that target specific depressive symptoms.
Export Options
About this article
Cite this article as:
Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression, Current Medicinal Chemistry 2021; 28 (22) . https://dx.doi.org/10.2174/0929867328666210104104938
DOI https://dx.doi.org/10.2174/0929867328666210104104938 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) 2-Acetylbenzofurans: Synthesis, Reactions and Applications
Current Organic Chemistry Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Antidepressant-Like Components of Hypericum perforatum Extracts: An Overview of Their Pharmacokinetics and Metabolism
Current Drug Metabolism Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets Serotonin Control of Dopaminergic Neurotransmission: Focus on 5-HT2 Receptors
Current Neuropharmacology Effect of PSEN1 mutations on MAPT methylation in early-onset Alzheimer’s disease
Current Alzheimer Research Lifestyle and Genetic Contributions to Cognitive Decline and Hippocampal Structure and Function in Healthy Aging
Current Alzheimer Research Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research Commentary: ADHD and Substance Abuse
Adolescent Psychiatry Role of Neuronal Guidance Cues in the Pathophysiology of Obesity: A Peripheral and Central Overview
Current Pharmaceutical Design Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies
Current Alzheimer Research ERRATUM 2
Current Neuropharmacology Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Current Pharmaceutical Design Fostering Resilience: Protective Agents, Resources, and Mechanisms for Adolescent Refugees' Psychosocial Well-Being
Adolescent Psychiatry Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design